This bill creates a new task force that brings together two government agencies—the Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA)—to work together more effectively on drug patents. Right now, these agencies operate somewhat independently, which can create confusion or inefficiencies when it comes to approving new drugs and protecting the patents that cover them.

The task force will do two main things. First, it will help the agencies share information about how they work and what they approve. For example, the USPTO will learn more about how the FDA evaluates new drug applications, and the FDA will learn about how the USPTO handles patent applications. Second, it will set up a formal system where the USPTO can ask the FDA for specific information about drug patents to help patent examiners do their jobs better, and the FDA will provide that information. This coordination is meant to make the patent process smoother for pharmaceutical companies developing new drugs and biologics (medicines made from living organisms), while also helping the government agencies work more efficiently together.

In practical terms, this means faster, more informed decisions on drug patents and fewer mix-ups between the two agencies. Pharmaceutical companies developing new medications should see a more streamlined process, and the government should be able to better protect innovation in the drug industry.

Interagency Patent Coordination and Improvement Act of 2025

Durbin, Richard J.

Interagency Patent Coordination and Improvement Act of 2025This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.